Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03-Reference-Cited by-同舟云学术

Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03

Published:2024-02-20 Issue:7 Volume:51 Page:2023-2035
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Wen Xuejun,Wang Rongxi,Xu Pengfei,Shi Mengqi,Shang Qingyao,Zeng Xueyuan,Zeng Xinying,Liu Jia,Wang Xin,Zhu Zhaohui,Guo Zhide,Chen Xiaoyuan,Zhang Jingjing^ORCID

Funder

National Medical Research Council, Singapore

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06634-9.pdf

Reference50 articles.

1. Lindsley CW, Müller CE, Bongarzone S. Diagnostic and therapeutic radiopharmaceuticals. J Med Chem. 2022;65:12497–9.

2. Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, et al. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD. Theranostics. 2022;12:7180–90.

3. Hu K, Li L, Huang Y, Ye S, Zhong J, Yan Q, et al. Radiosynthesis and preclinical evaluation of bispecific PSMA/FAP heterodimers for tumor imaging. Pharmaceuticals (Basel). 2022;15:383.

4. Abouzayed A, Yim CB, Mitran B, Rinne SS, Tolmachev V, Larhed M, et al. Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer. Pharmaceutics. 2019;11:358.

5. de Oliveira ÉA, Faintuch BL, Targino RC, Moro AM, Martinez RCR, Pagano RL, et al. Evaluation of GX1 and RGD-GX1 peptides as new radiotracers for angiogenesis evaluation in experimental glioma models. Amino Acids. 2016;48:821–31.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiopharmaceuticals Targeting Gastrin-Releasing Peptide Receptor for Diagnosis and Therapy of Prostate Cancer;Molecular Pharmaceutics;2024-08-06

2. Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection;Theranostics;2024

3. Development and biological evaluation of PSMA/FAP dual targeting radiotracers for prostate cancer imaging;Inorganic Chemistry Frontiers;2024